The signal transducer and activator of transcription 3 (STAT3) has emerged as a potential CCA therapeutic target because this signaling axis plays a key role in the inflammation associated with CCA carcinogenesis and the development of CCA5. This evidence concerns the gene STAT3 and cholangiocarcinoma.